Sagimet Biosciences

The company's business model is centered on the research and development of proprietary drug candidates, with revenue generated through strategic licensing agreements and milestone payments. A key example is a strategic licensing deal with Ascletis Bioscience for the development rights of its lead drug in Greater China. As a clinical-stage entity, its financial performance is characterized by significant investment in research and development, leading to operating losses while it works to bring its products to market. The company's primary clients are patients suffering from metabolic diseases with high unmet needs, particularly those with metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Sagimet's lead product candidate is denifanstat, an oral, once-daily pill. This drug is a selective FASN inhibitor designed to address the overproduction of palmitate, a fatty acid implicated in various diseases. The mechanism of action for denifanstat is to reduce the three primary drivers of MASH: fat accumulation, inflammation, and fibrosis. Clinical trial results have been promising; the Phase 2b FASCINATE-2 trial demonstrated that denifanstat achieved statistically significant improvements in MASH resolution without worsening of fibrosis. In addition to MASH, for which there are currently no approved treatments in the U.S. or Europe, Sagimet is exploring the potential of its FASN inhibitors for other indications, including various solid tumor cancers and acne.